Oruka Therapeutics
ORKA
17 hedge funds and large institutions have $4.16M invested in Oruka Therapeutics in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
30% more capital invested
Capital invested by funds: $3.2M → $4.16M (+$967K)
0.18% more ownership
Funds ownership: 0.51% → 0.69% (+0.18%)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
92% less call options, than puts
Call options by funds: $27K | Put options by funds: $331K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$907K |
| 2 |
State Street
Boston,
Massachusetts
|
+$240K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$129K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$115K |
| 5 |
Goldman Sachs
New York
|
+$48.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$149K |
| 2 |
PP
PDT Partners
New York
|
-$63K |
| 3 |
VF
Virtu Financial
New York
|
-$61K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$54.2K |
| 5 |
BlackRock
New York
|
-$48K |
ORKA Hedge Fund Activity: Q2 2021 in Review
17 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2021, worth a combined $4.16M — up 30% from $3.2M a quarter earlier.
Fund positioning in ORKA was balanced in Q2 2021: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $907K. The largest seller was Morgan Stanley, exiting entirely with an estimated $149K sold.
- 17 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $4.16M of Oruka Therapeutics stock for Q2 2021, up 30% quarter-over-quarter.
- 5 funds opened new Oruka Therapeutics positions in Q2 2021 and 5 closed out, a net change of 0 holders.
- The largest Oruka Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $907K added.
- The largest Oruka Therapeutics seller in Q2 2021 was Morgan Stanley, an estimated $149K sold.
Based on aggregated 13F filings for Q2 2021.